Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Meiji to Discontinue Sale of Kobayashi Kako Products after Biz Suspension
February 26, 2021
-
BUSINESS MSD’s 9-Valent HPV Vaccine Now Available in Japan
February 25, 2021
-
REGULATORY Japan to Start Elderly Vaccine Rollout from April 12: Minister
February 25, 2021
-
BUSINESS Takeda Launches Japan PI/II Trial of Novavax COVID-19 Vaccine
February 25, 2021
-
REGULATORY MHLW to Revise Dyslipidemia Drug Development Guideline for 1st Time in 30 Years
February 25, 2021
-
BUSINESS Japan Pharma Market Shrinks 2.4% on COVID-19, Price Cuts: IQVIA
February 24, 2021
-
REGULATORY LDP to Set Up Project Team to Strengthen Pharma Sector, Eyes Proposal in May
February 22, 2021
-
ORGANIZATION PhRMA Japan Chief Urges Govt to Return to Pro-Innovation Path, Airs Grievances over Decision-Making on Off-Year Price Cuts
February 19, 2021
-
BUSINESS Mitsubishi Tanabe Accelerating Drug Discovery via Open Innovation, Early-Stage Data Sharing
February 18, 2021
-
REGULATORY Celgene’s CAR-T Liso-Cel Now in Line for Possible March Approval in Japan
February 18, 2021
-
REGULATORY Japan Launches COVID-19 Vaccination Program
February 18, 2021
-
BUSINESS Novo Training Its Sights on Oral Diabetes Market with Rybelsus, Not Switches from GLP-1 Injectables
February 17, 2021
-
REGULATORY COVID-19 Vaccine Being Rolled Out for 40,000 Healthcare Workers in Japan
February 17, 2021
-
BUSINESS Shionogi Pharma Set to Expand CDMO Biz with Continuous Manufacturing, Eyes 10 Billion Yen Sales in FY2024
February 17, 2021
-
REGULATORY 17 Firms Get Approval for Cymbalta Generics, June Listing Eyed
February 16, 2021
-
REGULATORY PMDA Review Report: Pfizer Vaccine’s Efficacy for Variants Not Gauged in Clinical Trials, Continued Info Collection Needed
February 16, 2021
-
BUSINESS Japan’s 1st Humira Biosimilar Hits Market
February 16, 2021
-
REGULATORY Japan Approves Pfizer’s COVID-19 Vaccine, Rollout Set for Mid Week
February 15, 2021
-
BUSINESS Japan Trial Now Underway for Gene Therapy Luxturna; Eyes Riveted on Its Price Tag
February 12, 2021
-
BUSINESS Kobayashi Kako Chief to Resign over Drug Mix-Up, Lousy Manufacturing and Cover-Ups
February 10, 2021
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…